Immune-Onc Therapeutics, Inc
Immune-Onc Therapeutics, Inc. is a private, clinical-stage oncology company dedicated to discovering and developing novel biotherapeutics targeting myeloid cell inhibitory receptors. The company has a differentiated pipeline with a focus on targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) and is advancing several promising therapeutics for blood cancers and solid tumors.